News | December 05, 2014

Research Uncovers new way to Help Predict Outcomes for TAVR Patients

A retrospective analysis from the Minneapolis Heart Institute Foundation reveals that tricuspid regurgitation (TR) can help doctors predict which patients may have poor outcomes from the TAVR procedure

Clinical Trial, Heart valve repair, TAVR

December 5, 2014 – An estimated quarter of a million of older adults are diagnosed with aortic valve stenosis each year. And the treatment options, which include open-heart surgery to replace the aortic valve and less invasive transcatheter aortic valve replacement (TAVR), come with serious risks as well, including death.

New research from the Minneapolis Heart Institute Foundation has uncovered a way to help interventional cardiologists better predict which patients are at higher risk for death following TAVR, allowing both patient and surgeon to discuss a potentially different treatment plan.

Cardiologists and heart surgeons already look closely at tricuspid regurgitation (TR) in patients who are candidates for surgical aortic valve replacement, because the condition can tell them how likely the patient is to benefit from the procedure. This new research shows that TR may help cardiologists identify patients who are good (or poor) candidates for the minimally invasive TAVR procedure too.

To assess the impact of TR on TAVR outcomes, MHIF researchers analyzed the medical records of 129 TAVR patients. They looked at TR both before the procedure (baseline) and 30 days after, and classified the condition as none, mild, moderate or severe. The cases were divided into two groups according to baseline TR: none (n=89) and significant (anything worse than mild) (n=32). Survival following TAVR was significantly worse both in patients with significant TR and in patients who developed late TR (TR that had worsened to either moderate or severe at 30 days follow-up). The results were independent of baseline left ventricular ejection fraction (LVEF).

“While we don’t know yet whether this is cause and effect or TR is simply a marker for poor heart function,” said co-researcher Robert Schwartz, M.D., FACC, FAHA, “TR status and severity should be included in TAVR risk assessments to guide treatment decisions and aid in prognosis.”

For more information: www.mplsheart.org


Related Content

News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
News | Heart Valve Technology

Jan. 25, 2025—A new study presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that ...

Home January 27, 2025
Home
News | Heart Valve Technology

Jan. 6, 2025 — Medtronic plc has announced it received CE (Conformité Européenne) Mark for the Harmony Transcatheter ...

Home January 06, 2025
Home
News | Heart Valve Technology

Sept. 1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid ...

Home September 04, 2024
Home
News | Heart Valve Technology

June 27, 2024 — The sheer scale of undiagnosed heart valve disease in our aging population has been revealed for the ...

Home June 27, 2024
Home
News | Heart Valve Technology

June 21, 2024 — UC San Francisco interventional cardiologists and interventional echocardiographers recently performed ...

Home June 21, 2024
Home
News | Heart Valve Technology

June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial ...

Home June 10, 2024
Home
Subscribe Now